A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PD-L1 / PD-1 ligand

[Related PubMed/MEDLINE]
Total Number of Papers: 233
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PD-L1  (>> Co-occurring Abbreviation)
Long Form:   PD-1 ligand
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer. AGR, DC, NSCLC, OS, PD, PD, PFS
2020 Checkpoint inhibitor therapy in preclinical sepsis models: a systematic review and meta-analysis. BTLA, CLP, CPIs, CTLA-4, PD-1
2020 Efficacy of PD-1 blockade therapy and T cell immunity in lung cancer patients. ICIs, PD-1
2020 Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern. irAE, PD-1
2020 PD-1/PD-L1-dependent immune response in colorectal cancer. CRC, mAbs, MSI, PD-1
2020 PD-L1 expression is an unfavourable prognostic indicator in Asian renal cell carcinomas. CC, DFS, PD-1, RCC, TPS
2020 Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections. ICIs, irAEs, NSCLC, PD-1
2020 Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma. GBM, PD-1
2020 Stromal PD-1+ tumor-associated macrophages predict poor prognosis in lung adenocarcinoma. TAMs
10  2020 TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer. CI, ICB, NSCLC, PD-1, PFS, TCR
11  2020 Tumour-intrinsic resistance to immune checkpoint blockade. CTLA-4, PD1
12  2019 Aberrant upregulation of PDK1 in ovarian cancer cells impairs CD8+ T cell function and survival through elevation of PD-L1. DCA, JNK, PD-1, PDK1
13  2019 Analysis of the transcriptomic features of microsatellite instability subtype colon cancer. MSI
14  2019 Cardiovascular toxicities associated with immune checkpoint inhibitors. CTLA-4, ICIs
15  2019 Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma. ccRCC, PD-1, TIIC, VEGF-TKIs
16  2019 Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA. CTLA-4, GCA, IC, PB, PD-1, TABs, Th, VISTA
17  2019 Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer. NACT, NSCLC, PD-1
18  2019 Enhanced Programmed Death 1 and Diminished Programmed Death Ligand 1 Up-Regulation Capacity of Post-Activated Lupus B Cells. anti-BCR, IL-2, PD-1, SLE
19  2019 Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies. CTLA-4, ICIs, IMH, irAEs
20  2019 Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer. CTCs, MCA, PD-1
21  2019 Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. NCRs
22  2019 Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions. HNSCC, ICIs, PD-1
23  2019 Immunological Agents Used in Cancer Treatment. CTLA-4, ICI, irAEs
24  2019 In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1). chPD-1, PD-1
25  2019 Inhibition of COX-2 and EGFR by Melafolone Improves Anti-PD-1 Therapy through Vascular Normalization and PD-L1 Downregulation in Lung Cancer. COX-2, EGFR, LLC, PD-1, TGF-beta, VEGF
26  2019 Invasive Pulmonary Aspergillosis Complicated by Carbapenem-Resistant Pseudomonas aeruginosa Infection During Pembrolizumab Immunotherapy for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature. p-IPA, PD
27  2019 KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. NSCLC, OS, PD-1, PFS, TMB
28  2019 Lymph node migratory dendritic cells modulate HIV-1 transcription through PD-1 engagement. ART, DCs, IC, IC-L, LNs, Tfh
29  2019 Macrophages participate in the immunosuppression of condyloma acuminatum through the PD-1/PD-L1 signaling pathway. CA, ELISA, IL-10, PD-1
30  2019 MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. GSK3B, HCC, PDCD1
31  2019 MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers. CHOL, CTLA-4, DFS, GBM, KIRC, LGG, lncRNAs, LUAD, MIR155HG, OS, SKCM, UVM
32  2019 Myasthenia gravis induced by avelumab. MG
33  2019 Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1). PD-1
34  2019 Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature. BMS, PD, PD, USPTO, WIPO
35  2019 PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma. CSCC, PD-1
36  2019 PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. APCs, CTLA-4, PD-1
37  2019 Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab. BEV, PD-1, VEGF
38  2019 Predicting tumour response to anti-PD-1 immunotherapy with computational modelling. MHC
39  2019 Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PD-1 receptor. ILC, PD-1, PE, TM
40  2019 Programmed death-1 receptor (PD-1) and PD-ligand-1 (PD-L1) expression in non-small cell lung cancer and the immune-suppressive effect of anaerobic glycolysis. PD-1, TILs
41  2019 Structural insights and binding analysis for determining the molecular bases for programmed cell death protein ligand-1 inhibition. ---
42  2019 Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects. PD-1
43  2019 The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation. MDSC
44  2019 The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. CTLA-4, PD1
45  2019 The FG Loop of PD-1 Serves as a "Hotspot" for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy. mAbs, PD-1
46  2019 The prognostic impact of programmed cell death 1 and its ligand and the correlation with epithelial-mesenchymal transition in thymic carcinoma. EMT, IHC, IT, TC
47  2019 The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients. Abs, anti-AChR, CR, MG, PD-1
48  2019 The role of the PD-1/PD-L1 axis in macrophage differentiation and function during pregnancy. DMs, IRF, NP, PD-1, qRT-PCR, rh, RM
49  2019 Which place for avelumab in the management of urothelial carcinoma? ADCC, EMEA, FDA, ICI, PD-1, UC
50  2019 WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer. ALDH, PD-1, TNBCs
51  2019 XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients. AFP, BC, CA, CEA, HER, IL, lnc, XCI
52  2019 [Immune checkpoint inhibition in Merkel cell carcinoma]. MCC, PD
53  2018 Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. CI, PD-1
54  2018 Association of genetic variants of PD1 with recurrent pregnancy loss. PD1, RPL, SNPs
55  2018 Avelumab for the treatment of urothelial cancer. PD-1, UC
56  2018 Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFbeta enhance the efficacy of cancer immunotherapy. CTLA-4, PD-1, TGF-beta
57  2018 Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. CTLA-4, irAEs, mAbs
58  2018 Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer. MMR, NGS, NSCLC, PFS, POLE, TILs, TMBs
59  2018 Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma. PD-1, T-VEC
60  2018 Correlation of PD-1/PD-L1 Signaling Pathway with Treg/Th17 Imbalance from Asthmatic Children. PD-1, Th17
61  2018 ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). ESCMID, ESGICH, mAb, PD, PML, VZV
62  2018 Expression of programmed death ligand-1 and programmed death 1 in hepatocellular carcinoma and its clinical significance. HCC, PD-1
63  2018 Expression pattern of immunosurveillance-related antigen in adult T cell leukaemia/lymphoma. ATLL, beta2m, HLA, PD
64  2018 Frameshift events predict anti-PD-1/L1 response in head and neck cancer. CRs, OS, PRs, SCCHN, TMB
65  2018 High response rate to PD-1 blockade in desmoplastic melanomas. PD-1
66  2018 Immune Checkpoint Inhibitors to Treat Malignant Lymphomas. CTLA-4, PD-1
67  2018 Immune Checkpoints as the Immune System Regulators and Potential Biomarkers in HIV-1 Infection. CTLA-4, HIV, LAG3, TIM3
68  2018 Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells. DLBCL, NOS, EBV, HL, HRS, PD-1, PTCL-TFH
69  2018 Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. CTL, ICI, MDSC, mUC, PD1, PMN
70  2018 Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer. CTLA-4, NSCLC, PD-1
71  2018 In-vitro effect of pembrolizumab on different T regulatory cell subsets. CTLA-4, FOXP3, HD, LAP, PBC, PBMC, PD-1, Treg
72  2018 Intratumoral immune cells expressing PD-1/PD-L1 and their prognostic implications in cancer: a meta-analysis. CI, HR, PD-1
73  2018 Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. cHL, HRS, MHC, PD-1, PD-L2, PFS
74  2018 Manipulation of the immune system for cancer defeat: a focus on the T cell inhibitory checkpoint molecules. CTLA-4, PD-1
75  2018 Mechanisms of Drug Resistance in Melanoma. CTLA-4, MAPK, PD
76  2018 Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. CTCs, HR
77  2018 Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases. CSCC, PD-1
78  2018 NK cells for PD-1/PD-L1 blockade immunotherapy: pinning down the NK cell. PD-1
79  2018 Nonsmall cell lung cancer from HIV-infected patients expressed programmed cell death-ligand 1 with marked inflammatory infiltrates. HIV, NSCLC, PD-1
80  2018 Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). IUO, TIS
81  2018 PD-1 and cancer: molecular mechanisms and polymorphisms. ---
82  2018 PD-1 Controls Follicular T Helper Cell Positioning and Function. PD-1, TCR
83  2018 PD-1/PD-L1 regulates Treg differentiation in pregnancy-induced hypertension. NP, PBMCs, PD-1, PIH, Treg
84  2018 PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma. AEG, DFS, OS, PD-1, TILs
85  2018 Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility. cHL, PD-1
86  2018 Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. CI, ORR, OS, PD-1, PFS, RECIST v1.1, TRAEs
87  2018 Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. GMCI
88  2018 Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma. MM, PD-1, RRMM
89  2018 Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy. CTLA-4, PD1
90  2018 Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States. anti-PD-1, IHC, mNSCLC
91  2018 Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy. ---
92  2018 Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. anti-CCP, ICIs, irAEs
93  2018 Rheumatologic symptoms in oncologic patients on PD-1 inhibitors. BWH, CTLA-4, irAEs, PMR, RCC
94  2018 Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection. alphaPD-L1, CHB, ETV, HBV, IFN-gamma, PD-1, sAg, WHV
95  2018 Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. AID, irAE, NSCLC, PD
96  2018 Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report. HNSCC, IL
97  2018 Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer. PD-1
98  2018 Systemic Therapy for Hepatocellular Carcinoma: Latest Advances. CTLA-4, EHS, HCC, PD-1, TACE
99  2018 The altered PD-1/PD-L1 pathway delivers the 'one-two punch' effects to promote the Treg/Th17 imbalance in pre-eclampsia. PD-1, PE, Treg
100  2018 The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. ccRCC, CI, nccRCC, OS, PD-1, TTF